Answers are grounded in this paper and cite their sources.
OBJECTIVES: We aimed to determine the rate of facial pain misdiagnosis leading to the use of CBZ, OXC or eslicarbazepine (ESL), along with the associated clinical features. METHODS: We conducted a service evaluation of patients seen in a single tertiary-care headache centre to identify patients with any exposure to CBZ, OXC, or ESL from June 2014 to April 2024. Final diagnoses were reviewed and patients with inappropriate usage or previous misdiagnosis of trigeminal neuralgia were characterized. RESULTS: Of the 226 patients prescribed CBZ/OXC/ESL, 190 had headache or neuralgia indications. Crucially, only 65 patients (34%) were appropriately prescribed for trigeminal neuralgia, SUNHA or other neuralgias. Eight patients misdiagnosed with trigeminal neuralgia and not exposed to CBZ/OXC/ESL were identified. Of those either inappropriately treated with CBZ/OXC/ESL or potentially-misdiagnosed-as-trigeminal neuralgia (n=133), migraine was among the most common (79%; 44% migraine only) final diagnosis. The main clinical features in those misdiagnosed were facial involvement of pain (75%), unilateral pain (69%), throbbing (55%), stabbing (34%), sharp pain (33%) and allodynia (66%). Adverse effects were seen in 59% on carbamazepine and 55% on oxcarbazepine. DISCUSSION: In patients referred to a tertiary headache clinic, trigeminal neuralgia is over diagnosed and inappropriately treated with CBZ and its derivatives resulting in no useful clinical outcome and substantial side effects. Migraine with lateralised facial involvement is a common presentation resulting in this misdiagnosis.
No takes yet. Share an insight, caveat, or question.
Soontrapa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: